Genomic Vision Announces the Opening of a Receivership Proceedings
November 17 2023 - 12:00PM
Business Wire
Regulatory News:
Genomic Vision (FR0011799907 – GV, the “Company”), a
Euronext-listed biotechnology company that develops products and
services for the highly accurate characterization of transformed
cells, announces that, following the Company’s request (press
release of November 3, 2023), the Commercial Court of Nanterre,
decided on Novembre 15, 2023 to open a receivership procedure.
The Court appointed:
- SELARL AJRS, mission led by Maître Thibaut MARTINAT, as
receiver;
- and Maitre Patrick LEGRAS DE GRANCOURT as judicial
administrator.
The Company's operations will continue during the observation
period, in accordance with legal requirements.
Press releases will be published regularly as the procedure
moves forward.
The suspension of the listing of Genomic Vision shares,
effective since November 6, is maintained until further notice.
***
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company that develops products
and services for the highly accurate characterization of genome
modifications. We deliver high-quality integrated genomic analysis
solutions to improve quality control and bioproduction standards of
advanced gene therapies at scale. Based on molecular combing
technology and artificial intelligence, The Company provides robust
quantitative measurements needed for high confidence
characterization of transformed cell lines and prediction of cell
line performance, in particular in the context of the
biomanufacturing processes of cell and gene therapies.
Genomic Vision’s molecular combing technology has further
applications in drug development of agents targeting DNA
replication and damage response mechanisms, visualizing DNA
replication kinetics and telomere length maintenance.
Genomic Vision, based near Paris in Bagneux, is a public company
listed in compartment C of Euronext’s regulated market in Paris
(Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
Member of the CAC® Mid & Small and CAC® All-Tradable
indices
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on April 28, 2023 under
number D.23-0383, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
Genomic Vision has set up a financing line in the form of
convertible notes with warrants (OCABSA) with its Financing
partner. The shares resulting from the conversion or exercise of
the aforementioned securities will, in general, be sold on the
market, which could create downward pressure on the share price as
well as a dilution.
Shareholders could therefore suffer a loss of their invested
capital due to a significant decrease in the value of the company's
shares. The company has carried out several dilutive financing
operations, and investors are advised to be very careful before
making a decision to invest in the company's securities.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231117977803/en/
Genomic Vision Aaron Bensimon Chairman of the Management
Board Tel.: +33 1 49 08 07 51 investisseurs@genomicvision.com
NewCap France Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Visionary (NASDAQ:GV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Visionary (NASDAQ:GV)
Historical Stock Chart
From Apr 2023 to Apr 2024